A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients with MASH and F2/F3 Fibrosis

Phase 3

Not yet recruiting

• Conditions: MASH; NASH; Metabolic Dysfunction-associated Steatohepatitis; Noncirrhotic Metabolic Dysfunction-associated Steatohepatitis; Nonalcoholic Steatohepatitis; Nonalcoholic Fatty Liver
• Interventions: Drug: Denifanstat; Drug: Placebo

• Registration Number: NCT06594523
• Lead Sponsor: Sagimet Biosciences Inc.

Brief Summary

A randomized, double-blind, placebo-controlled Phase 3 study to determine if denifanstat 50 mg or 25 mg is effective, as compared to placebo, in resolving MASH without the worsening of fibrosis and/or in fibrosis regression without the worsening of steatohepatitis.

Detailed Description

Approximately 1260 patients (including at least 60% of F3 patients) will be enrolled to receive either denifanstat 50 mg (580 patients), placebo (580 patients), or denifanstat 25 mg (100 patients).

Study Timeline

• Study First Submitted: 2024-09-10
• Study First Submitted QC: 2024-09-10
• Study First Posted: 2024-09-19
• Status Verified: 2024-10
• Last Update Submitted: 2024-11-14
• Last Update Posted: 2024-11-18
• Study Start: 2024-12
• Primary Completion: 2030-12
• Study Completion: 2030-12

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 1260

Inclusion Criteria

1. Willing and able to participate in the study and provide written informed consent.

2. Adults between 18 and 75 years of age.

3. Body mass index (BMI) ≥23 kg/m^2 for Asian patients and ≥25 kg/m^2 for patients of other races.

4. Presence of metabolic risk factor(s), as follows:

   1. T2DM.

      OR

   2. 2 out of 4 of the following:

      • BMI ≥30 kg/m^2.
      • Hypertension, or on active antihypertensive treatment.
      • Elevated fasting serum TGs or on active treatment for hypertriglyceridemia.
      • Reduced fasting serum HDL-c or on active treatment for dyslipidemia.

5. For patients with T2DM:

   • HbA1c ≤9.5%.
   • Metformin, insulin, dipeptidyl peptidase-4 inhibitors (DPP4-Is), sodium-glucose transport protein-2 inhibitors (SGLT2-Is), and alpha-glucosidase inhibitors (α-GIs): stable dose for at least 12 weeks prior to qualifying liver biopsy and screening.
   • Sulfonylureas (SUs) and glinides: stable dose with no history of relevant hypoglycemia for at least 12 weeks prior to qualifying liver biopsy and screening.
   • GLP-1 RA: stable dose for at least 18 weeks prior to start of screening.

6. Noncirrhotic, biopsy-proven MASH with:

   1. A fibrosis stage of F2 or F3.

   2. NAS ≥4 with at least a score of 1 in each of the following NAS components:

      • Steatosis (scored 0 to 3).
      • Hepatocyte ballooning (scored 0 to 2).
      • Lobular inflammation (scored 0 to 3).

7. A qualifying historical liver biopsy within 6 months before the screening visit. Historical biopsy results will be confirmed by central reading.

   If there is no available historical liver biopsy within this time period, a liver biopsy must be performed during the screening period. Patients should be deemed likely to have MASH F2/F3 fibrosis prior to proceeding to a liver biopsy, as indicated by the following:

   1. FibroScan.

      • Liver stiffness measurement (LSM) ≥8.5 kPa.
      • Controlled attenuation parameter (CAP) ≥280 dB/m.

   2. Aspartate aminotransferase (AST) >20 U/L.

8. Stable ALT and AST levels.

Read More

Exclusion Criteria

1. Previous intake of an approved MASH medication.

2. Exclusionary laboratory values:

   1. ALT and/or AST >5 × ULN.
   2. ALP ≥2 × ULN.
   3. Total serum bilirubin concentration >1.3 mg/dL.
   4. Serum albumin concentration <3.5 g/dL.
   5. INR >1.3 except for patients receiving anticoagulant treatment.
   6. Platelet count <140,000/μL.
   7. Fasting TG level ≥500 mg/dL.
   8. eGFR <45 mL/min/1.73 m^2.

3. History of excessive alcohol intake for a period of more than 3 consecutive months within 1 year prior to screening.

4. Presence of cirrhosis on liver histology according to the assessment of the central reader.

5. Current or historical clinically evident hepatic decompensation.

6. Evidence of another form of active liver disease.

7. Positive serologic evidence of current infectious liver disease.

8. MELD score ≥12.

9. Planned or history of liver transplantation.

10. Prior or planned bariatric surgery.

11. Gain or loss of >5% of body weight in the 3 months or >10% of body weight in the 6 months prior to screening, qualifying liver biopsy, and the baseline visit (V1).

12. Any of the following within 6 months prior to the baseline visit (V1):

    1. Myocardial infarction.
    2. CABG/PTCA.
    3. Unstable angina.
    4. Transient ischemic attack, stroke, or cerebrovascular disease.

13. Unstable or undiagnosed arrhythmias.

14. Uncontrolled high BP.

15. Malignancy with a complete remission date within 5 years prior to the baseline visit (V1).

16. Any current or history of hepatocellular carcinoma.

17. Diabetes other than T2DM.

18. Uncontrolled hypothyroidism.

19. Any other known serious disease or other disease which in the Investigator's opinion would exclude the patient from participating in the study.

20. Previous intake of an approved MASH medication, unless there is at least a 6-month wash-out period between the last date of intake of the approved MASH medication and date of screening.

21. Use of a nonpermitted concomitant medication within 30 days or 5 half-lives prior to the qualifying liver biopsy and screening.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Denifanstat 50 mg	Denifanstat	Denifanstat tablet, orally, once daily
Denifanstat 25 mg	Denifanstat	Denifanstat tablet, orally, once daily
Placebo	Placebo	Placebo tablet, orally, once daily

Primary Outcome Measures

Name	Time	Method
Dual Primary Efficacy Endpoint 1: Interim Analysis: MASH Resolution (denifanstat 50 mg compared to placebo)	52 weeks	Proportion of patients who achieve MASH resolution (defined as NAS\* of 0 for ballooning, and 0 or 1 for inflammation) without worsening of fibrosis stage at Week 52.; \*NAS: nonalcoholic fatty liver disease activity score
Dual Primary Efficacy Endpoint 2: Interim Analysis: Improvement in Fibrosis (denifanstat 50 mg compared to placebo)	52 weeks	Proportion of patients who achieve at least a 1-point improvement in fibrosis stage and without worsening of steatohepatitis (defined as no increase in NAS\* for ballooning, inflammation, or steatosis) at Week 52.
Primary Endpoint: End of Study Analysis: Liver-related Composite Clinical Outcome (denifanstat 50 mg compared to placebo)	234 weeks	Time to first occurrence of any event from the following composite clinical outcome: death from any cause; histopathologic progression to cirrhosis; liver transplant; Model for End-Stage Liver Disease (MELD) score ≥15; Liver decompensation event defined by: Ascites requiring chronic diuretic treatment, Hepatic encephalopathy grade 2 or above requiring at least a 24-hour hospitalization, Variceal hemorrhage requiring hospitalization and transfusion of blood.